Access Pharmaceuticals (ACCP: OTCBB) is an emerging specialty pharma company developing and commercializing propriety products for the treatment and supportive care of cancer patients. MuGard, its FDA approved treatment for oral mucositis, is commercially launched in Europe, and will launch in the US and Asian in 1Q 2010. ProLindac, which is in pivotal clinical trials, is a new and improved version of Sanofi-Aventis’ Eloxatin, a DACH Platinum chemotherapeutic. Thiarabine is in human trials for the treatment of leukemias and lymphomas. Lastly, ACCP has collaborations in the areas of oral insulin and oral human growth hormone, using it’s proprietary Cobalamin based oral drug delivery platform.
Jeffrey Davis, CEO of Access Pharmaceuticals, talks about a product for cancer patients and trials of orally administered insulin
16th Apr 2010, 10:40 am
Jeffrey Davis, CEO of Access Pharmaceuticals, talks about a well received product for cancer patients that’s being rolled out globally, a novel drug delivery platform that tricks the body into thinking that it’s absorbing vitamin B12, and trials of a form of insulin that can be orally administered.
No investment advice
The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.
You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
